Fundamentals of Biotechnology

Submitted by: -
ECE – F
Motilal Nehru National Institute of Technology
Allahabad
Prayagraj, Uttar Pradesh
 Students in the group:
Name Registration Topic covered
Number
1. Omansh 20234111 Clinical
Awasthi Biotechnology
2. Piyush 20234117 Modern
Mishra Biotechnology
3. Pragyan Ansh 20234119 Natural
Biotechnology
4. Prakriti Singh 20234120 Marine
Biotechnology
5. Pranav Sanas 20234122 Challenge 1
6. Purushottam 20234221 Challenge 2
Kumar
7. Rishabh Patel 20234135 Challenge 3
8. Rudraksha 20234141 Challenge 4
Shukla
9. Sachin 20234144 RingCentral
Kumar
Mishra
10. Sneha 20234161 Full Labour
Jain Compliance in
international
markets
11. Tanishq 20234170 Cost efficient
Pandey market entry
12. Timmy 20234512 Expert global
Suresh employee support
13. Utpal 20234174 Streamline
Yadav Overseas
Operation
 Current challenges and their
possible solutions in various

Biotechnology is technology that utilizes biological systems,

living organisms or parts of this to develop or create different
products. Such conventional cycles typically use the living
organisms in their regular structure (or further created by
rearing), while the more present-day type of biotechnology will
for the most part include a further developed change of the
natural framework or organism. With the improvement of
hereditary designing during the 1970s, research in
biotechnology grew quickly due to the additional opportunity to
make changes in the organisms’ hereditary material (DNA).
Today, biotechnology covers many different disciplines. New
technologies and products are developed every year within the
areas of example - medicine (development of new medicines
and therapies), agriculture (development of genetically
modified plants, biofuels, biological treatment) or industrial
biotechnology (production of chemicals, paper, textiles and
food).

Types of Biotechnology
Following are the types of biotechnology; clinical
biotechnology (red), modern biotechnology (white), natural
biotechnology (green), and marine biotechnology (blue).

1. Clinical Biotechnology (red)

It is about human wellbeing and medication. In this way,
clinical biotechnology will include delivering new drug
drugs, antibodies, immunizations, and then some.

Red biotechnology offers a great deal of significant worth to

the drug business and the clinical calling. It assists with
upgrading patients’ personal satisfaction while likewise
mitigating the experience of agony and languishing.

2. Modern Biotechnology (white)

Modern biotechnology influences numerous areas, like the
material, food, and energy areas. Its attention is on utilizing
 innovation to make new cycles with the utilization of less
normal assets and energy when contrasted with regular
strategies.

Along these lines, modern biotechnology utilizes living cells

got from sources like plants, microorganisms, and yeast, and
makes items that need fewer assets (like energy) during their
creation.

3. Natural Biotechnology (green)

Natural Biotechnology is defined as a branch of biotechnology

that addresses environmental problems, such as the genetic
rescue of a species, the removal of pollution, renewable energy
generation or biomass production, all by using biological
processes for the protection and restoration of the quality of the
environment.
• The tools of biotechnology are having ever increasing
applications to conserving our natural environments.
• Examples: include the restoration of species and
ecosystems, phyto-remediation and microbial-
remediation of polluted soils and water, making cleaner,
more efficient and recyclable products, and increasing
our understanding of how the environment works at
molecular and cellular levels.
• The study of environmental biotechnology provides
opportunity in a broad range of specialties fundamental
to the understanding of plants, animals, and microbes
and their interaction with other organisms and
environments green biotechnology focuses on
advancements identified with agribusiness,
• for example, with regards to discovering ways of
delivering more grounded crops or making new
biopesticides to diminish the number of synthetic
compounds is utilized by ranchers

• Developing factory-grounded bioplastics that are kinder to

the climate can dwindle squander. Designing
microorganisms or shops that can cycle and wipe out
venoms and foreign substances in the climate.

• Using geographic information systems to find and collude

defiled spots as well as how the adulterants spread.
 4. Marine Biotechnology (blue)
Blue biotechnology is the fourth main type of biotechnology. It
refers to the study of marine organisms with a focus on using
these organisms for colourful mortal purposes. Similar to
creating new drugs or food supplements to enhance mortal
health.

Blue biotechnology makes use of a wide variety of marine

organisms and coffers for colourful tasks, similar to shellfish,
algae, and other substances. For illustration, the use of
ziconotide, a substance deduced from the venom of cone
draggers, is said to be an effective mortal anodyne.
The biotech sector is in a state of flux due to changing supply
change models, emphasis on quality control and quality
assurance, and efforts to optimize efficiency and control costs.
The demands of the industry put pressure on biotech
producers to deliver quality goods while achieving efficiency.
To balance these requirements, companies turn to automation,
technology, and collaboration.
Core challenges in biotech
production—and solutions
Challenge 1: Investor caution
Biotech production is extremely expensive. So too are the
research and development and FDA approval processes. There
is much risk with biotech investment. Failed development,
approval, or commercialization can ruin a fledgling business
and put a serious crimp in even more solidified companies.
Because of the risks, it is challenging for private biotech to
obtain financing. It takes a certain type of firm to analyse the
risks appropriately and to confidently put millions of dollars
into a business or a product. Yet, without funding, it is
difficult for biotech to acquire the necessary facilities,
equipment, and people to ensure quality, efficient production
processes.
Not only is funding difficult to acquire, but doing so can take
a lot of time, meetings, and persuasion. Private investors
spend a lot of time analysing risks and discussing potential
investments. The back-and-forth between the biotech firm and
the investor can add to delays in research, development, and
production.
One of the ways to remediate these financing challenges is to
expedite the communications process with investors. As
opposed to face-to-face meetings, or as a means of
intermittent conversations, biotech can utilize unified
communications systems (UCS). A UCS enables fast, reliable,
and consistent interactions across all popular modes of
interaction.

Challenge 2: Stringent FDA requirements

If it were just a matter of “making something,” biotech
production may not suffer as much from delays, inefficiency,
and waste. However, in the health and life sciences field,
federal regulations and the FDA have strict requirements as to
how you make your products and the end results. For these
reasons, biotech production is notoriously slow. This factor
contributes to the aforementioned uncertainty of investors,
who often prefer faster paydays.
To meet FDA requirements and ensure public safety, biotech
generally have more aggressive quality control and quality
assurance processes relative to companies in other industries.
Quality assurance processes are preventative measures to
increase the rate of quality products. Quality control is
processes used to identify products that aren’t up to standards.
Naturally, biotech can’t and don’t want to cut corners on
quality processes. However, there are steps to take that could
improve production efficiency without sacrificing quality. The
following are some examples:

• Automation.
Producers across many industries are focused on
automation to speed up various production and ancillary
processes. Analytics programs are used to detect product
discrepancies earlier in the process. Adjustments are
often automated to eliminate the need for manual
interventions.

• Internal collaboration.
Better collaboration between production managers,
quality control experts, and quality assurance experts can
expedite planning and response timelines. Again, a
unified communications system enables fast and flexible
interactions among leaders in these areas, including
planned meetings and impromptu interactions.
 • External collaboration.
Similarly, biotech producers need the capacity to interact
efficiently with FDA representatives to address any
concerns during approval and production processes.
Collaboration with industry partners is critical as well.

Challenge 3: Supply chain uncertainty and

risk
One of the most significant obstacles to biotech producers is
something that is largely out of their hands. Biotech relies
heavily on a consistent and flexible supply of raw materials
needed for production. However, there are sometimes factors
that adversely impact the ability of channel partners to meet
these expectations.
The pandemic, for instance, created major disruptions to many
transportation systems that biotech relies on to get raw
materials in a timely manner. Delays in raw material supply
led to subsequent disruptions to production processes.
Rather than just reacting to adverse circumstances, many
biotech producers have gone on the offensive to gain more
visibility into their supply chains. Artificial intelligence
software is used to identify potential industry bottlenecks.
Assessments of materials requirements among competitors
also offers some insight into potential supply shortages.
Identifying potential disruptions to transportation methods
early also allows for faster adjustments to alternatives.
Producers can only do so much on their own to prepare for
supply chain issues. Close relationships with channel partners
are essential to an effective, collaborative strategy. This is
another relationship where a UCS becomes invaluable for
agile and efficient interactions. Suppliers can quickly and
easily contact producers as soon as issues develop. Producers
can similarly reach out to supplier reps at the first sign of
trouble.

Challenge 4: Limited industry experts

The entire life sciences sector has been hampered by a lack of
industry experts. A limited talent pool makes it harder to
implement any of the other strategies discussed for resolving
production issues. In addition to concerns about available
talent, employed experts are so burdened with their workload,
that it is harder to keep up with industry trends.
Producers face a double-edged dilemma. They must invest in
attracting experts in a limited pool, but they must also invest
in training to keep current employees up-to-date.
Increased reliance on automation can help reduce the talent
burden. Thus, producers need to consider whether to amplify
investment in modern technology, including foundational
communications systems, or more people.

RingCentral solves biotech bottlenecks

Much of the burden on biotech producers can be managed

more effectively through supply chain collaboration. To
collaborate, producers need a strong tech infrastructure that
includes a top digital communications solution. The right tech
setup supports efforts to balance quality with cost-efficient
operations.
RingCentral’s unified communications system has enabled
companies across numerous industries to optimize
communication across all major platforms. It also allows for
easy integration with other software solutions and applications
popular among producers.
How International PEO
Helps Biotech Rise Above
Obstacles
An International PEO partner acts as a company’s
international Employer of Record, enabling quick entry into
new markets, full compliance with labour regulations, and
ongoing support of global employees. International PEO helps
biotech firms overcome three key challenges by providing:
• Full labour compliance in international
markets:
When biotech HR leaders have their hands full
recruiting and retaining talent and legal teams are busy
maintaining compliance with various regulatory
authorities, keeping up with international labour laws is
an unneeded headache. International PEO relieves the
burden by staying ahead of changing employment
regulations in every market. Through international PEO,
biotech companies avoid the hefty fines and legal fees
that come with non-compliance.
• Cost-efficient market entry:
For biotech firms already facing budget constraints,
establishing an entity to operate in a new market is a
significant expenditure. Setup can take months
and require $20,000 of initial investment, with annual
maintenance fees averaging $200,000. International PEO
expedites market entry, enabling companies to legally
begin operations in a matter of days. Working with an
International PEO provider helps biotech firms avoid the
costly and lengthy entity setup process so they can
quickly generate revenue and hire employees in new
markets.

• Expert global employee support:

Considering the time and resources that go into biotech
hiring, the scarcity of talent, and the high cost of
turnover, firms must maximize employee retention.
When HR teams cannot adequately assist global workers
spread across markets, attrition rates rise. An
International PEO partner helps by providing expert
 support to every member of a biotech company’s global
workforce. By answering every question related to pay,
benefits, and more, International PEO enables an optimal
employee experience—no matter where teams are
located.

Streamline Overseas Operations with

Velocity Global
Velocity Global enables biotech and life sciences companies
to simplify hiring and find new clients in over 185 markets
worldwide. Our experts assist with every step of the
expansion process—from planning and employee onboarding
to ensuring ongoing compliance—so companies can continue
searching for innovative medical solutions and driving their
businesses forward. Biotechnology has a lot of scope abroad.
Some of the top-most countries offering ample opportunities
for biotechnologists include Canada, China, Denmark, France,
the U.K., Germany, and Ireland.